PHAXIAM Therapeutics (XPAR:PHXM) Change In Inventory: €0.00 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics Change In Inventory?

PHAXIAM Therapeutics XPAR:PHXM 38 Change In Inventory is €0.00 Mil as of Sep. 2023. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

PHAXIAM Therapeutics's change in inventory for the quarter that ended in Sep. 2023 was €0.00 Mil. It means PHAXIAM Therapeutics's inventory stayed the same from Jun. 2023 to Sep. 2023 .

PHAXIAM Therapeutics's change in inventory for the fiscal year that ended in Dec. 2022 was €0.00 Mil. It means PHAXIAM Therapeutics's inventory stayed the same from Dec. 2021 to Dec. 2022 .

PHAXIAM Therapeutics's Total Inventories for the quarter that ended in Sep. 2023 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PHAXIAM Therapeutics  (XPAR:PHXM) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PHAXIAM Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

PHAXIAM Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PHAXIAM Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Change In Inventory Related Terms

PHAXIAM Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Change In Inventory Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.22 1.04 0.36 0.00 0.00

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €0.00 Mil mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a Change In Inventory of €0.00 Mil as of Sep. 2023. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Change In Inventory too high?
PHAXIAM Therapeutics' current Change In Inventory is €0.00 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Change In Inventory compare to VRTX and REGN?
PHAXIAM Therapeutics' Change In Inventory of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current Change In Inventory of €0.00 Mil. The current Change In Inventory is €0.00 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current Change In Inventory is €0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price